Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
If you have been diagnosed with an incurable blood cancer- multiple myeloma, each remission brings a sense of relief. Relief turns to anxiety when remission becomes relapse. Each remission becomes shorter until nothing more can be done.
However the article linked and excerpted below will bring hope to even the most heavily treated myeloma patient out there.
I have lived in complete remission since ’99 by living an evidence-based, non-toxic, anti-MM lifestyle through nutrition, supplementation, bone health, lifestyle and mind-body therapies. I consider what I do to be a non-toxic take on metronomic cancer therapy or low-dose maintenance therapy such as low-dose Revlimid.
As always, conventional oncology minimizes the impact of side effects in the article below. But if you are quad or penta-refractory MM patient you might not care.
Whether you are debating treatment options, currently undergoing treatment and experiencing painful side effects, or trying to figure out how to stay in remission, I want to share what I’ve learned from 19 years of complete remission from Multiple Myeloma.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Do you have multiple myeloma? Have you relapsed? Scroll down the page and write a question or a comment. I will reply to you ASAP.
“Patients with heavily treated multiple myeloma have promising response rates when treated with a combination of selinexor (KPT-330) and low-dose dexamethasone, according to the results of a Phase 2b clinical trial…
The Phase 2b STORM trial (NCT02336815) is a multi-center, single-arm study designed to evaluate selinexor in combination with low-dose dexamethasone in heavily treated multiple myeloma patients. The study enrolled 78 patients, 48 of whom had quad-refractory disease, and 30 of whom had penta-refractory disease.
Patients with quad-refractory disease are those who previously received two proteasome inhibitors: Velcade (bortezomib) and Kyprolis (carfilzomib), and two immunomodulatory agents: Revlimid (lenalidomine) and Pomalyst (pomalidomide). Also, their disease is refractory (does not respond) to at least one treatment of each category, and has progressed after their most recent treatment.
Those with penta-refractory disease are similar to patients with quad-refractory disease but are also refractory to an anti-CD38 monoclonal antibody, such as Darzalex (daratumumab) or isatuximab.
“Although treatment of multiple myeloma has improved dramatically, eventually many patients will develop refractory disease, no longer responding to any of the immunomodulatory agents and proteasome inhibitors commonly used (quad-refractory). These patients will also eventually progress on anti-CD38 monoclonal antibodies, which we refer to as penta-refractory disease…” “These are clearly the patients with the highest unmet need, as they have no remaining viable treatment options.”
Importantly, the study’s overall response rate (ORR) was 20.5 percent, with those with quad-refractory disease having an ORR of 20.8 percent and those with penta-refractory disease showing an ORR of 20 percent.
The researchers report that the side effect profile of selinexor was similar to that observed in previous trials, with no safety signals identified.
“We are currently unaware of any other therapy, oral or intravenous, reporting such activity in these difficult-to-treat patients who have exhausted all available therapies,” Stewart said…
In addition to the STORM study, Karyopharm has also started the Phase 1b/2 STOMP multi-arm clinical trial (NCT02343042) to evaluate selinexor and low-dose dexamethasone in combination with currently existing therapies for the multiple myeloma population, including Velcade, Pomalyst, or Revlimid. The combinations will be evaluated in separate arms, and selinexor will be tested in doses of once and twice a week.
Dose escalation has already been completed for the Velcade arm, and the recommended dose has been determined. This will provide information for a new Phase 3 study Karyopharm intends to initiate…
“Myeloma continues to be an incurable blood cancer in most patients and our main goal in treating refractory disease is to induce responses and maintain them as long as possible,” said Dr. Sagar Lonial, MD, professor and chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine and chief medical officer at Emory’s Winship Cancer Institute.
“In addition to these new data with oral selinexor and low-dose dexamethasone, the emerging clinical data from selinexor in combination with [Velcade], including in proteasome-inhibitor refractory disease, suggests a synergistic effect and favorable safety profile. These data are quite exciting and will form the basis for future studies,” Lonial said.”
[…] Heavily Treated Multiple Myeloma Patients Have Options […]Reply